Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera. The companies agreed to an ...

Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the fast-growing and competitive ...

Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...

Investors once speculated that Pfizer might consider acquiring Viking. Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new Chinese biotech OTR Therapeutics to work on drugs for metabolic diseases.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the ...

These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...